ICYMI One of the issues in #RNA therapeutic development is the cost of the process, along with lengthy timelines. However, would the application of Moore’s Law for computing provide a roadmap to overcoming those obstacles? As Kyle Studey discusses in his post, Rise of the Machine, artificial intelligence (#AI) could be the next big step for drug developers. https://lnkd.in/gABnx8tM
About us
Aldevron is proud to be part of Danaher. Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
- Website
-
http://www.aldevron.com
External link for Aldevron
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Fargo, North Dakota
- Type
- Privately Held
- Founded
- 1998
- Specialties
- Plasmid DNA, Messenger RNA (mRNA), Recombinant Proteins, CRISPR/Cas9, cGMP, GMP-Source, Gene Therapy, Cell Therapy, Vaccine Development, and Gene Editing
Locations
-
Primary
Get directions
4055 41st Ave S
Fargo, North Dakota 58104, US
-
Get directions
5602 Research Park Blvd
Suite 112
Madison, Wisconsin 53719, US
-
Get directions
3100 University Dr S
Fargo, North Dakota 58103, US
Employees at Aldevron
Updates
-
We love Jeremy Ostrowski -- a former Aldevron-ite who's now rockin it as a Talent Program Manager Danaher Life Sciences. He's kind of a big deal here in our home town of Fargo, ND!
Get ready to start your day with a bang! Hear from our very own rockstar, Jeremy Ostrowski, a lifelong Disrupter and member of our committee! Can’t wait to see you all THIS October! 🎸🎸 #disrupthr #disrupthrfm #dhrfm
-
As the field of mRNA-based medicines advances, both developers and regulatory agencies are prioritizing safety. The presence of double-stranded RNA (dsRNA) impurities, a byproduct of mRNA synthesis by in vitro transcription (IVT), can compromise the safety as well as the potency of mRNA vaccines and therapeutics. Don't miss this Fierce Biotech Webinar where we will introduce our innovative solutions that include Codex® HiCap T7 RNA Polymerase. The production of mRNA using HiCap minimizes dsRNA formation during IVT, which may eliminate the need for a secondary chromatography step in downstream purification. This paves the way for the development of safer and more potent mRNA-based medicines with simpler and more economical manufacturing workflows. Secure your spot today! https://lnkd.in/gj289Y44
-
-
From new approaches to therapeutic development to dealing with the biggest challenges in gene editing, Alex Liu came away inspired from the International Society for Cell & Gene Therapy annual meeting. He shares some of what he sees as the potential of cell and gene editing in the near future in his blog post, Breaking Boundaries for Future Treatments. https://lnkd.in/gsFBzEkY
-
-
We are lucky to have Sharon King as an important part of our team!
As a voice for the rare disease community, a recent op-ed in STAT really hit home for me. The article focuses on how the FDA’s rare pediatric disease priority review voucher program will disappear unless Congress reauthorizes it before September 30. As NORD's Pamela Gavin shares in the byline, more than 30 million Americans live with a rare disease, and nearly half are children – the program disappearing would be a devastating end for patients and their families eagerly waiting for treatment. At Aldevron, we are committed to advocating for individuals with #rarediseases by helping develop the tools to create breakthrough treatments, and we understand how important increased funding and programming is in this often-forgotten space. We must continue to push the government to incentivize #drugdevelopment for rare diseases, ensuring that patients continue to have hope for their future. #PRVs #RareDisease #FDA
-
As the field of mRNA-based medicines advances, both developers and regulatory agencies are prioritizing safety. The presence of double-stranded RNA (dsRNA) impurities, a byproduct of mRNA synthesis by in vitro transcription (IVT), can compromise the safety as well as the potency of mRNA vaccines and therapeutics. Don't miss this Fierce Biotech Webinar where we will introduce our innovative solutions that include Codex® HiCap T7 RNA Polymerase. The production of mRNA using HiCap minimizes dsRNA formation during IVT, which may eliminate the need for a secondary chromatography step in downstream purification. This paves the way for the development of safer and more potent mRNA-based medicines with simpler and more economical manufacturing workflows. Secure your spot today! https://lnkd.in/gsJcdZ2v
-
-
ICYMI With Biological Safety Levels (BSL), many gene therapy developers and manufacturers aim for BSL I in the manufacturing process. But as Aldevron’s Cody Grasswick points out, there are reasons to consider BSL II when some regulations and controls come into the mix. https://lnkd.in/g5XGFrmt
-
One of the issues in #RNA therapeutic development is the cost of the process, along with lengthy timelines. However, would the application of Moore’s Law for computing provide a roadmap to overcoming those obstacles? As Kyle Studey discusses in his post, Rise of the Machine, artificial intelligence (#AI) could be the next big step for drug developers. https://lnkd.in/gATPtHAs
-
-
With Biological Safety Levels (BSL), many gene therapy developers and manufacturers aim for BSL I in the manufacturing process. But as Aldevron’s Cody Grasswick points out, there are reasons to consider BSL II when some regulations and controls come into the mix. https://lnkd.in/gNeZZ-Pk
Should You Level Up Your BSL?
aldevron.com